Stocks That Hit 52-Week Lows On Friday
Friday's session saw 169 companies set new 52-week lows.
Theravance Biopharma Earnings Preview
Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Monday, 2023-08-07. Here’s what investors…
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties' collaboration agreement with Theravance Biopharma Inc
Earnings Scheduled For May 8, 2023
Companies Reporting Before The Bell
• HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.
Theravance Biopharma 13D Filing Reports Weiss Asset Management LP Reports 11.79% Stake In Co
1
NAMES OF REPORTING PERSONS.
Weiss Asset Management LP
BIP
Theravance Biopharma, Inc. Highlights 2022 Accomplishments And 2023 Key Targets; Said Seeks To Achieve Non-GAAP1 Profitability By 2H 2023
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced its 2022 Accomplishments and 2023 Key Targets.
Earnings Scheduled For November 7, 2022
Companies Reporting Before The Bell
• NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.
A Preview Of Theravance Biopharma’s Earnings
Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement.
Analysts estimate that Theravance Biopharma will report an earnings per share (EPS) of $-0.18.
Here’s Why Theravance Biopharma Shares Are Moving
Theravance Biopharma Inc (NASDAQ: TBPH) shares are trading higher by 2.78% to $10.35 Monday afternoon after the company authorized a $250 million capital return program.
What Else?
Theravance Outlines $250M Capital Return Program; To Repurchase GSK’s Entire Holdings
Theravance Biopharma Inc (NASDAQ:TBPH) is buying back over 9.6 million shares from GSK plc (NYSE:GSK) for roughly $94 million, according to an…